Federico Albrecht, MD

home / authors / federico-albrecht-md

Articles

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

Between the Lines™ Podcast: Incorporating Real-World Evidence into Clinical Decisions in NSCLC

Matthew Fowler;Lyudmila Bazhenova, MD;Federico Albrecht, MD

January 14th 2022

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

Increasing Rates of Real-World Studies in EGFR-Mutated NSCLC

Lyudmila Bazhenova, MD;Federico Albrecht, MD

November 24th 2021

Drs Lyudmila Bazhenova and Federico Albrecht comment on the significance of real-world data collection in EGFR-mutated non–small cell lung cancer and suggest what can be done to increase the rates of real-world studies conducted.

Using Various Sources of Information to Guide Management of EGFR-Mutated NSCLC

Lyudmila Bazhenova, MD;Federico Albrecht, MD

November 16th 2021

Recommendations for how to best treat patients with EGFR-mutated non–small cell lung cancer when there are discrepancies between clinical trial data and real-world evidence.

Referring to Real-World Evidence When Managing EGFR-Mutant NSCLC

Lyudmila Bazhenova, MD;Federico Albrecht, MD

November 11th 2021

Information provided by real-world data that is noted to be the most valuable to thoracic oncologists and others who manage patients with EGFR-mutant non–small cell lung cancer.

EGFR-Mutant NSCLC: Incorporating RWE Into Treatment Decisions

Lyudmila Bazhenova, MD;Federico Albrecht, MD

November 4th 2021

Drs Lyudmila Bazhenova and Federico Albrecht comment on the pros and cons of real-world evidence to guide treatment decisions for patients with EGFR-mutant non–small cell lung cancer.

EGFR-Mutant NSCLC: Addressing Gaps When Collecting Data

Lyudmila Bazhenova, MD;Federico Albrecht, MD

October 28th 2021

Federico Albrecht, MD, reacts to limitations regarding the designs and outcomes of randomized controlled trials in EGFR-mutant non–small cell lung cancer and describes his interest in collecting real-world data.

Presentation: Benefits and Limitations of RWE: Lessons From EGFR Mutation-Positive NSCLC

Lyudmila Bazhenova, MD;Federico Albrecht, MD

October 21st 2021

Dr. Lyudmila Bazhenova presents a recently published article by Nazha B, et al., “Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.”